These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 33176943)
21. Discovery and characterization of novel FGFR1 inhibitors in triple-negative breast cancer via hybrid virtual screening and molecular dynamics simulations. Wang Y; Shen Z; Chen R; Chi X; Li W; Xu D; Lu Y; Ding J; Dong X; Zheng X Bioorg Chem; 2024 Sep; 150():107553. PubMed ID: 38901279 [TBL] [Abstract][Full Text] [Related]
22. Natural Product-Inspired Discovery of Naphthoquinone-Furo-Piperidine Derivatives as Novel STAT3 Inhibitors for the Treatment of Triple-Negative Breast Cancer. Fan C; Lou S; Shen C; Liao J; Ni H; Chen S; Zhu Z; Hu X; Xie W; Zhao H; Cui S J Med Chem; 2024 Sep; 67(17):15291-15310. PubMed ID: 39226127 [TBL] [Abstract][Full Text] [Related]
23. One-pot three-component synthesis of novel spirooxindoles with potential cytotoxic activity against triple-negative breast cancer MDA-MB-231 cells. Eldehna WM; El-Naggar DH; Hamed AR; Ibrahim HS; Ghabbour HA; Abdel-Aziz HA J Enzyme Inhib Med Chem; 2018 Dec; 33(1):309-318. PubMed ID: 29281924 [TBL] [Abstract][Full Text] [Related]
24. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis. Wawruszak A; Luszczki JJ; Kalafut J; Okla K; Halasa M; Rivero-Muller A; Stepulak A Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357442 [TBL] [Abstract][Full Text] [Related]
25. Discovery of N-(Naphtho[1,2-b]Furan-5-Yl) Benzenesulfonamides as Novel Selective Inhibitors of Triple-Negative Breast Cancer (TNBC). Chen Y; Tang Y; Mao B; Li W; Jin H; Zhang L; Liu Z Molecules; 2018 Mar; 23(3):. PubMed ID: 29547591 [TBL] [Abstract][Full Text] [Related]
26. Discovery of acetophenone/piperazin-2-one hybrids as selective anti-TNBC cancer agents by causing DNA damage. Zhang ZJ; Liao YT; Wang W; Yang C; Li D; Shao LD Bioorg Med Chem Lett; 2024 Aug; 108():129802. PubMed ID: 38777278 [TBL] [Abstract][Full Text] [Related]
27. The discovery of novel, potent ERR-alpha inverse agonists for the treatment of triple negative breast cancer. Du Y; Song L; Zhang L; Ling H; Zhang Y; Chen H; Qi H; Shi X; Li Q Eur J Med Chem; 2017 Aug; 136():457-467. PubMed ID: 28525844 [TBL] [Abstract][Full Text] [Related]
28. Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer. Singleton DC; Dechaume AL; Murray PM; Katt WP; Baguley BC; Leung EY BMC Cancer; 2020 May; 20(1):470. PubMed ID: 32450839 [TBL] [Abstract][Full Text] [Related]
29. Exploring Marine-Derived Ascochlorins as Novel Human Dihydroorotate Dehydrogenase Inhibitors for Treatment of Triple-Negative Breast Cancer. Luo X; Cai G; Guo Y; Gao C; Huang W; Zhang Z; Lu H; Liu K; Chen J; Xiong X; Lei J; Zhou X; Wang J; Liu Y J Med Chem; 2021 Sep; 64(18):13918-13932. PubMed ID: 34516133 [TBL] [Abstract][Full Text] [Related]
30. Exploring the Molecular Mechanism of Cinnamic Acid-Mediated Cytotoxicity in Triple Negative MDA-MB-231 Breast Cancer Cells. Pal A; Tapadar P; Pal R Anticancer Agents Med Chem; 2021; 21(9):1141-1150. PubMed ID: 32767960 [TBL] [Abstract][Full Text] [Related]
32. Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer. Zhao YQ; Yin YQ; Liu J; Wang GH; Huang J; Zhu LJ; Wang JH Acta Pharmacol Sin; 2016 Sep; 37(9):1237-50. PubMed ID: 27397540 [TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and structure-activity relationship studies of a focused library of pyrimidine moiety with anti-proliferative and anti-metastasis activities in triple negative breast cancer. Yao D; Zhou Y; Zhu L; Ouyang L; Zhang J; Jiang Y; Zhao Y; Sun D; Yang S; Yu Y; Wang J Eur J Med Chem; 2017 Nov; 140():155-171. PubMed ID: 28923383 [TBL] [Abstract][Full Text] [Related]
34. The Interaction of PI3K Inhibition with Homologous Recombination Repair in Triple Negative Breast Cancer Cells. Guney Eskiler G J Pharm Pharm Sci; 2019; 22(1):599-611. PubMed ID: 31804921 [TBL] [Abstract][Full Text] [Related]
35. Discovery of potent CSK inhibitors through integrated virtual screening and molecular dynamic simulation. Chen R; Wang Y; Shen Z; Ye C; Guo Y; Lu Y; Ding J; Dong X; Xu D; Zheng X Arch Pharm (Weinheim); 2024 Sep; 357(9):e2400066. PubMed ID: 38809025 [TBL] [Abstract][Full Text] [Related]
36. Multipathway regulation induced by 4-(phenylsulfonyl)morpholine derivatives against triple-negative breast cancer. Yang FW; Mai TL; Lin YJ; Chen YC; Kuo SC; Lin CM; Lee MH; Su JC Arch Pharm (Weinheim); 2024 May; 357(5):e2300435. PubMed ID: 38314850 [TBL] [Abstract][Full Text] [Related]
37. DR5 antibody conjugated lipid-based nanocarriers of gamma-secretase inhibitor for the treatment of triple negative breast cancer. Pindiprolu SKSS; Krishnamurthy PT; Dev C; Chintamaneni PK Chem Phys Lipids; 2021 Mar; 235():105033. PubMed ID: 33385372 [TBL] [Abstract][Full Text] [Related]
39. Discovery of novel steroidal-chalcone hybrids with potent and selective activity against triple-negative breast cancer. Hou Q; Lin X; Lu X; Bai C; Wei H; Luo G; Xiang H Bioorg Med Chem; 2020 Dec; 28(23):115763. PubMed ID: 32992255 [TBL] [Abstract][Full Text] [Related]
40. A styrylpyrone dimer isolated from Aniba heringeri causes apoptosis in MDA-MB-231 triple-negative breast cancer cells. de Souza KFS; Tófoli D; Pereira IC; Filippin KJ; Guerrero ATG; Paredes-Gamero EJ; de Fatima Cepa Matos M; Garcez WS; Garcez FR; Perdomo RT Bioorg Med Chem; 2021 Feb; 32():115994. PubMed ID: 33477019 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]